Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?
The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma. It is also used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2010.229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549140039467008 |
|---|---|
| author | Gregory R. Tintinger Charles Feldman Annette J. Theron Ronald Anderson |
| author_facet | Gregory R. Tintinger Charles Feldman Annette J. Theron Ronald Anderson |
| author_sort | Gregory R. Tintinger |
| collection | DOAJ |
| description | The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma. It is also used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma, chronic obstructive pulmonary disease, cystic fibrosis, and viral bronchiolitis, which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this mini-review is to present evidence for the cysteinyl leukotrien–independent mechanisms of action of montelukast and their potential clinical relevance. |
| format | Article |
| id | doaj-art-ffd26f7511cd484588f1c3725a18221c |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-ffd26f7511cd484588f1c3725a18221c2025-02-03T06:12:16ZengWileyThe Scientific World Journal1537-744X2010-01-01102403241310.1100/tsw.2010.229Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?Gregory R. Tintinger0Charles Feldman1Annette J. Theron2Ronald Anderson3Department of Internal Medicine, Faculty of Health Sciences, University of Pretoria, South AfricaDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaMedical Research Council Unit for Inflammation and Immunity, Department of Immunology, University of Pretoria, and Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South AfricaMedical Research Council Unit for Inflammation and Immunity, Department of Immunology, University of Pretoria, and Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South AfricaThe prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma. It is also used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma, chronic obstructive pulmonary disease, cystic fibrosis, and viral bronchiolitis, which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this mini-review is to present evidence for the cysteinyl leukotrien–independent mechanisms of action of montelukast and their potential clinical relevance.http://dx.doi.org/10.1100/tsw.2010.229 |
| spellingShingle | Gregory R. Tintinger Charles Feldman Annette J. Theron Ronald Anderson Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? The Scientific World Journal |
| title | Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? |
| title_full | Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? |
| title_fullStr | Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? |
| title_full_unstemmed | Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? |
| title_short | Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? |
| title_sort | montelukast more than a cysteinyl leukotriene receptor antagonist |
| url | http://dx.doi.org/10.1100/tsw.2010.229 |
| work_keys_str_mv | AT gregoryrtintinger montelukastmorethanacysteinylleukotrienereceptorantagonist AT charlesfeldman montelukastmorethanacysteinylleukotrienereceptorantagonist AT annettejtheron montelukastmorethanacysteinylleukotrienereceptorantagonist AT ronaldanderson montelukastmorethanacysteinylleukotrienereceptorantagonist |